PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense (“HAT”) in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of Health has informed PaxMedica that, following the treatment, the patient is recovering at home. The Rhodesiense strain of HAT is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi and many East African countries.

“The first use of PAX-101 to treat a critically ill patient with Stage 1 HAT infection is an important milestone for the company following years of investment in the formulation and commercial scale-up of Suramin, the active pharmaceutical ingredient of PAX-101, with the company’s supply chain partners. We were contacted by the government of Malawi after sustained shortages of IV Suramin in the region in the past year, and we could not ignore their pleas for help. Responding to this extraordinary request demonstrates our commitment to provide this essential medicine to some of the world’s most vulnerable people,” said Howard Weisman, CEO of PaxMedica.

To view the full press release, visit https://ibn.fm/BSPNB

About PaxMedica Inc.

PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. Its comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as autism spectrum disorder (“ASD”), as well as other critical areas within the neurology field. The company also intends to provide the rest of the world with an additional, reliable source of Suramin, the accepted standard of care for stage 1 Trypanosoma brucei rhodesiense. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. To learn more about PaxMedica and its transformative work, visit www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN